EVENTS

Wedbush Life Sciences MAC Best Ideas 2010 Conference

August 3, 2010, New York, NY

15th Congress of the European Hematology Association (EHA)

June 10-13, 2010, Barcelona, Spain

PRESENTATION DETAILS:

  • Clinical Activity in a Phase 1 Study of CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase p110δ, in Patients with B-Cell Malignancies
  • | View Presentation |
  • Preclinical results assessing selected chemokines in plasma and circulating CLL cells from patients in the Phase 1 clinical trial of CAL-101
  • | View Presentation |

2010 American Society of Clinical Oncology (ASCO) Annual Meeting

June 4-8, 2010, Chicago, IL

PRESENTATION DETAILS:

  • Interim Results from a Phase I Study of CAL-101, a Selective Oral Inhibitor of Phosphatidylinositol 3-Kinase p110δ Isoform, in Patients with Relapsed or Refractory Hematologic Malignancies
  • | View Presentation |

51st American Society of Hematology (ASH) Annual Meeting

Dec. 5-9, 2009, New Orleans, LA

PRESENTATION DETAILS:

  • Evidence of Clinical Activity in a Phase 1 Study of CAL-101, an Oral P110δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies
  • | View Presentation |
  • CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment
  • | View Presentation |

Thirteenth International Workshop on Chronic Lymphocytic Leukemia

Oct. 16-18, 2009, Barcelona, Spain

PRESENTATION DETAILS:

  • Preliminary Evidence of Clinical Activity in a Phase 1 Study of CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
  • | View Presentation |

The Biopharmaceutical
Conference in Europe

June 17-19, 2009, Monte Carlo

European Hematology Association 14th Congress

June 4-7, 2009, Berlin, Germany

PRESENTATION DETAILS:

American Society of Clinical Oncology Annual Meeting 2009

May 29 - June 2, 2009, Orlando, Florida

PRESENTATION DETAILS:

  • Preliminary Evidence of Clinical Activity in a Phase I Study of CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase (P13K), in Patients with Select Hematologic Malignancies.
  • | View Abstract |

    • Date/Time: Sat May 30, 8:00AM to 12:00PM
    Session: Developmental Therapeutics: Molecular Therapeutics
    Location: Level 2, West Hall C
    Abstract: #3543

American Society of Hematology's 50th Annual Meeting

December 6-9, 2008, San Francisco, CA

PRESENTATION DETAILS:

  • CAL-101, a potent selective inhibitor of the p110d isoform of phosphatidylinositol 3-kinase, attenuates PI3K signaling and inhibits proliferation and survival of Acute Lympoblastic Leukemia in addition to a range of other hematological malignancies
  • | View Presentation |

    • Date/Time: Sunday, December 7, 2008 4:30 PM - 6:00 PM
    Session: Acute Lymphocytic Leukemia - Biology and Pathophysiology Session
    Location: San Francisco Marriott, Golden Gate Hall
    Presenter: Brian Lannutti, Ph.D., Calistoga Pharmaceuticals